Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

@article{Nasrallah2008AtypicalAM,
  title={Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles},
  author={Henry A. Nasrallah},
  journal={Molecular Psychiatry},
  year={2008},
  volume={13},
  pages={27-35}
}
  • H. Nasrallah
  • Published 2008
  • Psychology, Medicine
  • Molecular Psychiatry
Atypical antipsychotic drugs offer several notable benefits over typical antipsychotics, including greater improvement in negative symptoms, cognitive function, prevention of deterioration, and quality of life, and fewer extrapyramidal symptoms (EPS). However, concerns about EPS have been replaced by concerns about other side effects, such as weight gain, glucose dysregulation and dyslipidemia. These side effects are associated with potential long-term cardiovascular health risks, decreased… 
View on Nature
nature.com
530 Citations
Highly Influential Citations
23
Background Citations
231
Methods Citations
2
Results Citations
13

530 Citations

Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis

It is argued that the metabolic and cardiovascular side effects of antipsychotics are primarily mediated by their ability to block peripheral dopamine receptors, which physiologically modulate sympathetic activity, and that these effects might be overcome by providing peripheral dopaminergic stimulation.

Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects

Emerging evidence suggests that antipsychotics have different liabilities to induce obesity, diabetes and dyslipidemia, however this diversity cannot be explained merely by drugs’pharmacodynamic profiles, highlighting the need for further research.

Paliperidone Extended-Release: Safety and Tolerability from a Metabolic Profile Perspective

The ER formulation of paliperidone may offer potential advantages over atypical antipsychotics such as risperidone, particularly with regard to side effects and compliance, but comparative studies are needed.

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

The metabolic and cardiovascular risks of various antipsychotic medications in adults and children are outlined, the disparities in health care are defined, and recommendations for screening and monitoring of patients taking these agents are made.

Understanding the Effects of Antipsychotics on Appetite Control

The receptor binding profile of various APDs is discussed in relation to the potential mechanisms by which they affect appetite, both for the development of new APDs, with lower appetite-stimulating effects, and because such insight may provide new knowledge about appetite regulation in general.

Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences

There seems to be a correlation between AAP’s higher clinical efficacy and increase risk of metabolic alterations, and a multidisciplinary approach combining psychoeducation and therapeutic drug monitoring (TDM) is proposed as a first-line strategy to avoid the MetS.

Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders

The neural mechanisms of currently existing atypical antipsychotic drugs and putative antipsychotics currently being investigated in preclinical and clinical studies are presented and how these relate to their effectiveness in mood disorders such as depression, anxiety, and post-traumatic stress disorder are presented.

Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia

It is proposed that, beyond its symptomatology in the central nervous system, schizophrenia is also characterized by pathophysiology in other organ systems directly related to metabolic control.

Unraveling the Mechanisms Underlying Olanzapine-Induced Insulin Resistance

The direct effects of second-generation AAPs on insulin resistance and postprandial gut hormone profiles following a mixed meal are examined and it is found that weight gain is secondary to weight gain in AAP-associated metabolic impairments.

GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?

...

References

SHOWING 1-10 OF 97 REFERENCES

A review of the effect of atypical antipsychotics on weight

  • H. Nasrallah
  • Psychology, Medicine
    Psychoneuroendocrinology
  • 2003

Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.

It is concluded that atypical antipsychotics continue to have notable risks of EPS, particularly akathisia, and that these agents also appear to increase the risk of the metabolic syndrome, though this effect seems most marked with clozapine and olanzapine.

Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.

  • J. SilvestreJ. Prous
  • Medicine, Psychology
    Methods and findings in experimental and clinical pharmacology
  • 2005
This study provides the first direct evidence to indicate that antipsychotic agents with high binding affinity to the muscarinic M3 receptor are associated with an elevated risk for type 2 diabetes.

Second-Generation (Atypical) Antipsychotics and Metabolic Effects

There is no evidence at this time to suggest that ziprasidone and aripiprazole treatment are associated with an increase in risk for diabetes, dyslipidaemia or other adverse effects on glucose or lipid metabolism, but case reports tentatively suggest that substantial weight gain or obesity may not be a factor in up to one-quarter of cases of new-onset diabetes.

Differential metabolic effects of antipsychotic treatments

  • D. Haupt
  • Psychology, Medicine
    European Neuropsychopharmacology
  • 2006

Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.

Although in its infancy, psychiatric pharmacogenetics will in the future aid clinical practice in the prediction of response and side effects, such as antipsychotic-induced weight gain, and minimize the current "trial and error" approach to prescribing.

Novel antipsychotics and new onset diabetes

Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.

In animals, remoxipride has minimal cataleptic effects at doses that block dopamine agonist-induced hyperactivity and these findings are predictive of antipsychotic activity with a low likelihood of extrapyramidal symptoms.

Effects of atypical antipsychotics on weight and serum lipid levels.

  • J. Meyer
  • Medicine, Psychology
    The Journal of clinical psychiatry
  • 2001
An understanding of appropriate monitoring for metabolic adverse effects is important for those who prescribe atypical antipsychotics, as is a working knowledge of behavioral and pharmacologic treatments for weight gain and hyperlipidemia.

Hyperglycemia associated with the use of atypical antipsychotics.

These studies indicate that hyperglycemia is not dose dependent, is reversible on cessation of treatment with clozapine or olanzapine, and reappears on reintroduction of these therapies.
...